The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2024 | A case report of CAR-T-related neurotoxicity presenting as delayed aseptic meningitis in MCL
In this video, Stefania Bramanti, MD, Humanitas Research Hospital, Rozzano, Italy, briefly describes the first case report of aseptic meningitis following CAR T-cell therapy. A 44-year-old male with late-stage mantle cell lymphoma (MCL) received CAR-T therapy with brexucabtagene autoleucel (brexu-cel) and was subsequently discharged from the hospital. However, at days 30 and 58 post-infusion, the patient presented with late-onset CAR T-cell-related neurotoxicity, which was eventually diagnosed as aseptic autoimmune meningitis. CAR T-cell re-expansion was observed both in the peripheral blood (PB) and cerebrospinal fluid (CSF). The patient’s neurological condition improved upon treatment with high-dose methylprednisolone and anakinra. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
